Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?

Journal Article (Journal Article)

The opioid epidemic has resulted in an increase in organ donors with hepatitis C virus (HCV) infection in the United States. With the development of direct-acting antiviral regimens that offer high sustained virologic response rates even in the setting of immunosuppression after transplantation, these HCV-viremic organs are now being offered to transplant candidates with or without preexisting HCV infection. Strategies for HCV treatment with HCV-viremic organs have included delayed and preemptive approaches. This review will discuss key studies in the different solid organ transplants, recent reports of adverse events, and ethical and regulatory considerations. The efficacy of current HCV therapies has created this important opportunity to improve survival for patients with end-organ failure through greater access to organ transplantation and decreased waitlist mortality rate.

Full Text

Duke Authors

Cited Authors

  • Kappus, MR; Wolfe, CR; Muir, AJ

Published Date

  • November 27, 2020

Published In

Volume / Issue

  • 222 / Suppl 9

Start / End Page

  • S794 - S801

PubMed ID

  • 33245347

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiaa420


  • eng

Conference Location

  • United States